Whittier Trust Co. Cuts Position in Solventum Co. (NYSE:SOLV)

Whittier Trust Co. cut its stake in Solventum Co. (NYSE:SOLV) by 14.7% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,965 shares of the company’s stock after selling 854 shares during the period. Whittier Trust Co.’s holdings in Solventum were worth $328,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Investment House LLC lifted its stake in Solventum by 111.3% in the fourth quarter. Investment House LLC now owns 76,171 shares of the company’s stock worth $5,032,000 after purchasing an additional 40,130 shares during the last quarter. Xponance Inc. lifted its stake in Solventum by 9.8% in the fourth quarter. Xponance Inc. now owns 21,014 shares of the company’s stock worth $1,388,000 after purchasing an additional 1,879 shares during the last quarter. Boston Partners bought a new stake in Solventum in the fourth quarter worth $110,378,000. Generali Asset Management SPA SGR bought a new stake in Solventum in the fourth quarter worth $659,000. Finally, Thrivent Financial for Lutherans lifted its stake in Solventum by 37.9% in the fourth quarter. Thrivent Financial for Lutherans now owns 12,721 shares of the company’s stock worth $863,000 after purchasing an additional 3,498 shares during the last quarter.

Analyst Ratings Changes

Several research firms have weighed in on SOLV. Mizuho boosted their price target on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. Morgan Stanley upped their price objective on shares of Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 5th. Wells Fargo & Company upped their price objective on shares of Solventum from $73.00 to $75.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. The Goldman Sachs Group upped their price objective on shares of Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research note on Monday, March 3rd. Finally, Piper Sandler upped their price objective on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $79.86.

Solventum Price Performance

SOLV stock opened at $74.00 on Monday. Solventum Co. has a 1 year low of $47.16 and a 1 year high of $85.92. The company has a market cap of $12.80 billion and a P/E ratio of 26.91. The firm has a 50-day moving average of $75.17 and a 200 day moving average of $71.61. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.